Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  HIV Infection

  Free Subscription


1 AIDS Res Hum Retroviruses
4 Clin Infect Dis
6 HIV Med
2 J Acquir Immune Defic Syndr
1 J Clin Immunol
2 J Infect Dis
2 J Med Virol
2 J Virol
3 Lancet
1 N Engl J Med
1 Nat Rev Neurol
1 Nature
10 PLoS One
1 PLoS Pathog
1 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. CHAMMARTIN F, Griessbach A, Kusejko K, Audige A, et al
    Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1.
    AIDS. 2023 Oct 12. doi: 10.1097/QAD.0000000000003751.
    PubMed         Abstract available

  2. CLAY CE, Hoover KW, Le Guen Y, Bennett CL, et al
    Estimates of HIV testing at Visits to U.S. emergency departments, 2014-2020.
    AIDS. 2023 Oct 11. doi: 10.1097/QAD.0000000000003750.
    PubMed         Abstract available

  3. MASENGA SK, Muchaili L, Hamooya BM
    Cardiovascular Outcomes Among Persons with HIV and Nonalcoholic Fatty Liver Disease.
    AIDS. 2023;37:1329-1331.

  4. PARKER VL, Baker ZL, Stone BJ, Singh K, et al
    High HIV prevalence in gestational trophoblastic neoplasia patients: experience from an expert UK treatment centre.
    AIDS. 2023 Oct 10. doi: 10.1097/QAD.0000000000003738.
    PubMed         Abstract available

  5. SILVA MS, Coutinho C, Torres TS, Peixoto EM, et al
    Mpox severity and associated hospitalizations among people living with HIV and related immunosuppression in Brazil.
    AIDS. 2023 Oct 7. doi: 10.1097/QAD.0000000000003748.
    PubMed         Abstract available

  6. CABRAL-PICCIN MP, Briceno O, Papagno L, Liouville B, et al
    CD8+ T cell priming is quantitatively but not qualitatively impaired in people with HIV-1 on antiretroviral therapy.
    AIDS. 2023 Oct 6. doi: 10.1097/QAD.0000000000003746.
    PubMed         Abstract available

    AIDS Res Hum Retroviruses

  7. LAPER S, Hileman CO, Block G, Erlandson KM, et al
    Perceived risks and benefits and frequency of cannabis use among people with HIV in different legal environments.
    AIDS Res Hum Retroviruses. 2023 Oct 12. doi: 10.1089/AID.2022.0144.
    PubMed         Abstract available

    Clin Infect Dis

  8. AMICK AK, Eskibozkurt GE, Hosek SG, Flanagan CF, et al
    Daily Oral Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Clin Infect Dis. 2023 Oct 12:ciad566. doi: 10.1093.
    PubMed         Abstract available

  9. CASTRO H, Sabin C, Collins IJ, Okhai H, et al
    Evolution of CD4 T-Cell count with age in a cohort of young people growing up with perinatally acquired HIV.
    Clin Infect Dis. 2023 Oct 11:ciad626. doi: 10.1093.
    PubMed         Abstract available

  10. STIER EA, Jain M, Joshi H, Darragh TM, et al
    Two-Year Incidence and Cumulative Risk and Predictors of Anal High-Grade Squamous Intraepithelial Lesions (anal precancer) among Women with HIV.
    Clin Infect Dis. 2023 Oct 8:ciad614. doi: 10.1093.
    PubMed         Abstract available

  11. HAYON J, Lupo S, Poveda C, Jones KM, et al
    Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk People with HIV Living in the United States.
    Clin Infect Dis. 2023 Oct 8:ciad616. doi: 10.1093.
    PubMed         Abstract available

    HIV Med

  12. GACIC N, Tulloch K, Money D, Tkachuk S, et al
    Daily ritonavir-boosted darunavir for viral suppression in pregnancy (DRV-P).
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13546.
    PubMed         Abstract available

  13. PAYRA S, Manjhi PK, Singh S, Kumar R, et al
    HIV cure: Are we going to make history?
    HIV Med. 2023 Oct 11. doi: 10.1111/hiv.13557.
    PubMed         Abstract available

  14. NDEGE R
    Sero-negative HIV, a need for presumptive HIV diagnosis in adults in developing countries.
    HIV Med. 2023 Oct 12. doi: 10.1111/hiv.13564.

  15. BEGRE L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, et al
    Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13561.
    PubMed         Abstract available

  16. FRANGE P, Veber F, Burgard M, Blanche S, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    HIV Med. 2023 Oct 8. doi: 10.1111/hiv.13562.
    PubMed         Abstract available

  17. FLYGEL TT, Hameiri-Bowen D, Simms V, Rowland-Jones S, et al
    Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease.
    HIV Med. 2023 Oct 7. doi: 10.1111/hiv.13565.
    PubMed         Abstract available

    J Acquir Immune Defic Syndr

  18. OMOZ-OARHE AE, Hughes MD, Bao Y, Short WR, et al
    Incidence and Predictors of Pregnancy in Women Enrolled in Large Multi-National HIV Treatment Trials of the AIDS Clinical Trials Group.
    J Acquir Immune Defic Syndr. 2023 Oct 9. doi: 10.1097/QAI.0000000000003299.
    PubMed         Abstract available

  19. MORRISON CA, Corbeil T, Kluisza L, Poku O, et al
    Identifying the Mental Health Effects of Cumulative Traumatic Exposure in HIV-Affected Youth: A Longitudinal Assessment.
    J Acquir Immune Defic Syndr. 2023 Oct 9. doi: 10.1097/QAI.0000000000003313.
    PubMed         Abstract available

    J Clin Immunol

  20. HARGARTEN JC, Anjum SH, Ssebambulidde K, Park YD, et al
    Tocilizumab as a Potential Adjunctive Therapy to Corticosteroids in Cryptococcal Post-infectious Inflammatory Response Syndrome (PIIRS): a Report of Two Cases.
    J Clin Immunol. 2023 Oct 10. doi: 10.1007/s10875-023-01592.
    PubMed         Abstract available

    J Infect Dis

  21. NAIDOO KK, Highton AJ, Baiyegunhi OO, Bhengu SP, et al
    Early initiation of antiretroviral therapy preserves the metabolic function of CD4+ T-cells in subtype C HIV-1 infection.
    J Infect Dis. 2023 Oct 6:jiad432. doi: 10.1093.
    PubMed         Abstract available

  22. PARK SY, Lindner MS, Brick K, Noll N, et al
    Detection of Mpox Virus Using Microbial Cell-free DNA: the Potential of Pathogen-Agnostic Sequencing for Rapid Identification of Emerging Pathogens.
    J Infect Dis. 2023 Oct 12:jiad452. doi: 10.1093.
    PubMed         Abstract available

    J Med Virol

  23. SHANG W, Cao G, Wu Y, Kang L, et al
    Spatiotemporal cluster of mpox in men who have sex with men: A modeling study in 83 countries.
    J Med Virol. 2023;95:e29166.
    PubMed         Abstract available

  24. LAGI F, Giacomelli A, Borghi V, Ciccullo A, et al
    Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    J Med Virol. 2023;95:e29149.
    PubMed         Abstract available

    J Virol

  25. SONG E, Lee SK, Dykxhoorn DM, Novina C, et al
    Correction for Song et al., "Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages".
    J Virol. 2023 Oct 13:e0093623. doi: 10.1128/jvi.00936.

  26. VAN DUIJN J, Stieh D, Fernandez N, King D, et al
    Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH.
    J Virol. 2023 Oct 9:e0112623. doi: 10.1128/jvi.01126.
    PubMed         Abstract available


  27. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    PubMed         Abstract available

  28. BALDEH M, Kizito S
    Call to action: HIV among adolescents in Sierra Leone.
    Lancet. 2023;402:1240.

  29. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.

    N Engl J Med

  30. DONOVAN J, Bang ND, Imran D, Nghia HDT, et al
    Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.
    N Engl J Med. 2023;389:1357-1367.
    PubMed         Abstract available

    Nat Rev Neurol

  31. ELLIS RJ, Marquine MJ, Kaul M, Fields JA, et al
    Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.
    Nat Rev Neurol. 2023 Oct 10. doi: 10.1038/s41582-023-00879.
    PubMed         Abstract available


  32. THADANI NN, Gurev S, Notin P, Youssef N, et al
    Learning from prepandemic data to forecast viral escape.
    Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06617.
    PubMed         Abstract available

    PLoS One

  33. CAPUCCI S, Wee EG, Schiffner T, LaBranche CC, et al
    Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
    PLoS One. 2023;18:e0293148.
    PubMed         Abstract available

  34. ESHETU HB, Kebede N, Bogale EK, Zewdie A, et al
    Knowledge of prevention of mother-to-child transmission of HIV among reproductive age women in high HIV/AIDS prevalent countries: A multilevel analysis of recent Demographic and Health Surveys.
    PLoS One. 2023;18:e0292885.
    PubMed         Abstract available

  35. MBOYA E, Mizinduko M, Balandya B, Mushi J, et al
    HIV burden and the global fast-track targets progress among pregnant women in Tanzania calls for intensified case finding: Analysis of 2020 antenatal clinics HIV sentinel site surveillance.
    PLoS One. 2023;18:e0285962.
    PubMed         Abstract available

  36. TIAM A, Paulin H, Machekano R, Oboho I, et al
    Rapid antiretroviral therapy initiation in patients with advanced HIV disease: 6-month outcomes of an observational cohort evaluation in Lesotho.
    PLoS One. 2023;18:e0292660.
    PubMed         Abstract available

  37. WU MC, Wang EY, Lai TW
    TAT peptide at treatment-level concentrations crossed brain endothelial cell monolayer independent of receptor-mediated endocytosis or peptide-inflicted barrier disruption.
    PLoS One. 2023;18:e0292681.
    PubMed         Abstract available

  38. AKISO M, Ameka M, Naidoo K, Langat R, et al
    Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy.
    PLoS One. 2023;18:e0286436.
    PubMed         Abstract available

  39. KAKANDE A, Ssemata AS, Muhumuza R, Atujuna M, et al
    Preferences for oral PrEP dosing among adolescent boys and young men in three sub-Saharan African countries.
    PLoS One. 2023;18:e0285132.
    PubMed         Abstract available

  40. MACDONALD J, Estcourt CS, Flowers P, Nandwani R, et al
    Improving HIV pre-exposure prophylaxis (PrEP) adherence and retention in care: Process evaluation and recommendation development from a nationally implemented PrEP programme.
    PLoS One. 2023;18:e0292289.
    PubMed         Abstract available

  41. KUMAKECH E, Acen J, Musinguzi M, Ebong D, et al
    Female-controlled dual protection methods: Prevalence, predictors, experiences and perceptions among young women living with HIV in northern Uganda-A mixed-method study protocol.
    PLoS One. 2023;18:e0290338.
    PubMed         Abstract available

  42. AZIZ N, Shih R, Alexopoulos N, Jamieson BD, et al
    Relationship among serum levels of IL-6, sIL-6R, s gp130 and CD126 on T-cell in HIV-1 infected and uninfected men participating in the Los Angeles Multi-Center AIDS Cohort Study.
    PLoS One. 2023;18:e0290702.
    PubMed         Abstract available

    PLoS Pathog

  43. PINKEVYCH M, Docken SS, Okoye AA, Fennessey CM, et al
    Timing of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication.
    PLoS Pathog. 2023;19:e1011660.
    PubMed         Abstract available


  44. CHECCHI M, Mesher D, Panwar K, Anderson A, et al
    The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Vaccine. 2023 Oct 9:S0264-410X(23)01162-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.